NCT00563602 is a Phase 4 clinical trial of Hemodynamic guided therapy in Portal Hypertension, sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau.

Who is sponsoring NCT00563602?

NCT00563602 is sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau.

What drugs are being tested in NCT00563602?

Interventions in NCT00563602: Hemodynamic guided therapy.

What condition does NCT00563602 study?

NCT00563602 studies Portal Hypertension, Complications of Cirrhosis.

Is NCT00563602 still recruiting?

NCT00563602 is currently status unknown. Last updated 22 November 2007.

Last reviewed 2007-11-22 · How we verify

NCT00563602

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized and Controlled Study of Endoscopic Ligation, Nadolol and Isosorbide Mononitrate vs Endoscopic Ligation and Nadolol Alone, or Associated With Isosorbide Mononitrate or Prazosin, Depending of the Hemodinamyc Response

Status unknown Phase 4 Last updated 22 November 2007

What this trial tests

Phase 4 trial testing Hemodynamic guided therapy in Portal Hypertension in 140 participants. Status unknown.

Timeline

1 August 2007

1 November 2007

Quick facts

Lead sponsor	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	140
Start date	1 August 2007
Estimated completion	1 November 2007
Sites	1 location across Spain

Drugs / interventions tested

Hemodynamic guided therapy

Conditions studied

Portal Hypertension — all drugs for Portal Hypertension →
Complications of Cirrhosis — all drugs for Complications of Cirrhosis →

Sponsor

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Who can join

Adults 18 to 80, any sex, with Portal Hypertension or Complications of Cirrhosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Rebleeding
Time frame: 1-2 Years

Sponsor's own description

This is a prospective trial of random distribution, open, parallel group, in which patients with esophagic variceal bleeding will be randomized into two treatment groups, after controlling acute bleeding. All patients received standard medical therapy with b-blockers and endoscopic ligation (LEV) of esophageal varices. The control group will be assigned to receive LEV + Nadolol + MNI. The experimental group will be assigned to receive treatment according to the hemodynamic response. All patients included in the experimental group received LEV and pharmacological treatment nadolol alone or combined with MNI or Prazosin (PZ)

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis.
Roberts D, Best LM, Freeman SC, Sutton AJ, et al · · 2021 · cited 16× · PMID 33837526 · DOI 10.1002/14651858.cd013155.pub2

Verify or expand the search:

Other recruiting trials for Portal Hypertension

Currently open trials in the same condition.

NCT07439939 — Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Place · recruiting
NCT07521332 — Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis · Phase 4 · recruiting
NCT07419724 — Construction of a Portal Hypertension Biobank · recruiting
NCT07116096 — Effect of Handgrip Strength on Portal Vein Hemodynamics in Patients With Liver Cirrhosis · NA · recruiting
NCT07080697 — A Study to Evaluate Splenectomy on Debridement for Acute Necrotizing Pancreatitis With Pancreatic Sinistral Portal Hyper · NA · recruiting

Other Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau trials

Trials by the same sponsor.

NCT07343882 — Quantification of Systemic Congestion by Ultrasound As a Predictor of Weaning Failure From Mechanical Ventilation · NA · not yet recruiting
NCT07530237 — Efficacy of Periarticular Vasoconstrictor Infiltration (PVI) in Reducing Bleeding and Postoperative Pain in Lumbar Fusio · active not recruiting
NCT07369310 — Comparing Biomarker-Guided DBS Programming With Standard Clinical Monopolar Programming · NA · not yet recruiting
NCT07314190 — Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodege · enrolling by invitation
NCT07239843 — Prospective Observational Study of the Relationship Between Sociodemographic Factors, Blood-based Biomarkers and Psychia · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00563602 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Last refreshed: 22 November 2007

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00563602.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing